The hardware and bandwidth for this mirror is donated by METANET, the Webhosting and Full Service-Cloud Provider.
If you wish to report a bug, or if you are interested in having us mirror your free-software or open-source project, please feel free to contact us at mirror[@]metanet.ch.

1.1 Introduction

In the previous vignette we have seen how we can use the CohortCharacteristics package to summarise a set of pre-specified characteristics of a study cohort. These characteristics included patient demographics like age and sex, and also concept sets and cohorts that we defined. Another, often complimentary, way that we can approach characterising a study cohort is by simply summarising all clinical events we see for them in some window around their index date (cohort entry).

To show how large scale characterisation can work we’ll first create a first-ever ankle sprain study cohort using the Eunomia synthetic data.

library(duckdb)
library(CDMConnector)
library(dplyr, warn.conflicts = FALSE)
library(PatientProfiles)
library(CohortCharacteristics)

con <- dbConnect(duckdb(), dbdir = eunomiaDir())
cdm <- cdmFromCon(
  con = con, cdmSchem = "main", writeSchema = "main", cdmName = "Eunomia"
)

cdm <- generateConceptCohortSet(
  cdm = cdm,
  name = "ankle_sprain",
  conceptSet = list("ankle_sprain" = 81151),
  end = "event_end_date",
  limit = "first",
  overwrite = TRUE
)

1.2 Large scale characteristics of study cohorts

To summarise our cohort of individuals with an ankle sprain we will look at their records in three tables of the OMOP CDM (condition_occurrence, procedure_occurrence, and drug_exposure) over two time windows (any time prior to their index date, and on index date). For conditions and procedures we will identify whether someone had a new record starting in the time window. Meanwhile, for drug exposures we will consider whether they had a new or ongoing record in the period.

Lastly, but important to note, we are only going to only return results for concepts for which at least 10% of the study cohort had a record.

lsc <- cdm$ankle_sprain |>
  summariseLargeScaleCharacteristics(
    window = list(c(-Inf, -1), c(0, 0)),
    eventInWindow = c(
      "condition_occurrence",
      "procedure_occurrence"
    ),
    episodeInWindow = "drug_exposure",
    minimumFrequency = 0.1
  )

tableLargeScaleCharacteristics(lsc)
CDM name
Eunomia
Cohort name
ankle_sprain
Variable name Estimate name Concept id Variable level
-inf to -1 0 to 0
condition_occurrence; event; standard
Streptococcal sore throat N(%) 28060 499(36.77%) -
Sprain of wrist N(%) 78272 148(10.91%) -
Osteoarthritis N(%) 80180 283(20.85%) -
Chronic sinusitis N(%) 257012 162(11.94%) -
Acute bronchitis N(%) 260139 767(56.52%) -
Otitis media N(%) 372328 909(66.99%) -
Concussion with no loss of consciousness N(%) 378001 185(13.63%) -
Acute viral pharyngitis N(%) 4112343 845(62.27%) -
Whiplash injury to neck N(%) 4218389 137(10.10%) -
Sinusitis N(%) 4283893 166(12.23%) -
Acute bacterial sinusitis N(%) 4294548 168(12.38%) -
Viral sinusitis N(%) 40481087 981(72.29%) -
Sprain of ankle N(%) 81151 - 1,357(100.00%)
procedure_occurrence; event; standard
Suture open wound N(%) 4125906 363(26.75%) -
Sputum examination N(%) 4151422 282(20.78%) -
Plain chest X-ray N(%) 4163872 137(10.10%) -
Bone immobilization N(%) 4170947 356(26.23%) -
drug_exposure; episode; standard
celecoxib N(%) 1118084 189(13.93%) -
Acetaminophen 160 MG Oral Tablet N(%) 1127078 559(41.19%) 199(14.66%)
Acetaminophen 325 MG Oral Tablet N(%) 1127433 737(54.31%) 330(24.32%)
Amoxicillin 250 MG / Clavulanate 125 MG Oral Tablet N(%) 1713671 499(36.77%) -
Penicillin G 375 MG/ML Injectable Solution N(%) 19006318 384(28.30%) -
Aspirin 81 MG Oral Tablet N(%) 19059056 842(62.05%) 470(34.64%)
Ampicillin 100 MG/ML Injectable Solution N(%) 19129655 193(14.22%) -
Penicillin V Potassium 250 MG Oral Tablet N(%) 19133873 491(36.18%) -
poliovirus vaccine, inactivated N(%) 40213160 994(73.25%) -
tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use N(%) 40213227 288(21.22%) -
hepatitis B vaccine, adult dosage N(%) 40213306 226(16.65%) -
Haemophilus influenzae type b vaccine, PRP-OMP conjugate N(%) 40213314 210(15.48%) -
Acetaminophen 21.7 MG/ML / Dextromethorphan Hydrobromide 1 MG/ML / doxylamine succinate 0.417 MG/ML Oral Solution N(%) 40229134 296(21.81%) -
Doxycycline Monohydrate 50 MG Oral Tablet N(%) 46233988 172(12.68%) -
Ibuprofen 200 MG Oral Tablet N(%) 19078461 - 192(14.15%)

As we can see we have identified numerous concepts for which at least 10% of our study population had a record. Often with larger cohorts and real patient-level data we will obtain many times more results when running large scale characterisation. One option we have to help summarise our results is to pick out the most frequent concepts. Here, for example, we select the top 5 concepts.

tableLargeScaleCharacteristics(lsc,
  topConcepts = 5
)
CDM name
Eunomia
Cohort name
ankle_sprain
Variable name Estimate name Concept id Variable level
-inf to -1 0 to 0
condition_occurrence; event; standard
Otitis media N(%) 372328 909(66.99%) -
Acute viral pharyngitis N(%) 4112343 845(62.27%) -
Viral sinusitis N(%) 40481087 981(72.29%) -
Sprain of ankle N(%) 81151 - 1,357(100.00%)
drug_exposure; episode; standard
poliovirus vaccine, inactivated N(%) 40213160 994(73.25%) -

1.3 Stratified large scale characteristics

Like when summarising pre-specified patient characteristics, we can also get stratified results when summarising large scale characteristics. Here, for example, large scale characteristics are stratified by sex (which we add as an additional column to our cohort table using the PatientProfiles package).

lsc <- cdm$ankle_sprain |>
  addSex() |>
  summariseLargeScaleCharacteristics(
    window = list(c(-Inf, -1), c(0, 0)),
    strata = list("sex"),
    eventInWindow = "drug_exposure",
    minimumFrequency = 0.1
  )

tableLargeScaleCharacteristics(lsc)
CDM name
Eunomia
Cohort name
ankle_sprain
Sex
overall Female Male
Variable name Estimate name Concept id Variable level
-inf to -1 0 to 0 -inf to -1 0 to 0 -inf to -1 0 to 0
drug_exposure; event; standard
celecoxib N(%) 1118084 189(13.93%) - 92(13.47%) - 97(14.39%) -
Acetaminophen 160 MG Oral Tablet N(%) 1127078 559(41.19%) 199(14.66%) 292(42.75%) 97(14.20%) 267(39.61%) 102(15.13%)
Acetaminophen 325 MG Oral Tablet N(%) 1127433 737(54.31%) 330(24.32%) 374(54.76%) 165(24.16%) 363(53.86%) 165(24.48%)
Amoxicillin 250 MG / Clavulanate 125 MG Oral Tablet N(%) 1713671 499(36.77%) - 244(35.72%) - 255(37.83%) -
Penicillin G 375 MG/ML Injectable Solution N(%) 19006318 384(28.30%) - 169(24.74%) - 215(31.90%) -
Aspirin 81 MG Oral Tablet N(%) 19059056 842(62.05%) 470(34.64%) 427(62.52%) 245(35.87%) 415(61.57%) 225(33.38%)
Ampicillin 100 MG/ML Injectable Solution N(%) 19129655 193(14.22%) - 98(14.35%) - 95(14.09%) -
Penicillin V Potassium 250 MG Oral Tablet N(%) 19133873 491(36.18%) - 256(37.48%) - 235(34.87%) -
poliovirus vaccine, inactivated N(%) 40213160 994(73.25%) - 501(73.35%) - 493(73.15%) -
tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use N(%) 40213227 288(21.22%) - 151(22.11%) - 137(20.33%) -
hepatitis B vaccine, adult dosage N(%) 40213306 226(16.65%) - 128(18.74%) - 98(14.54%) -
Haemophilus influenzae type b vaccine, PRP-OMP conjugate N(%) 40213314 210(15.48%) - 112(16.40%) - 98(14.54%) -
Acetaminophen 21.7 MG/ML / Dextromethorphan Hydrobromide 1 MG/ML / doxylamine succinate 0.417 MG/ML Oral Solution N(%) 40229134 296(21.81%) - 132(19.33%) - 164(24.33%) -
Doxycycline Monohydrate 50 MG Oral Tablet N(%) 46233988 172(12.68%) - 94(13.76%) - 78(11.57%) -
Ibuprofen 200 MG Oral Tablet N(%) 19078461 - 192(14.15%) - 93(13.62%) - 99(14.69%)
Nitrofurantoin 5 MG/ML Oral Suspension N(%) 920300 - - 84(12.30%) - - -
{7 (Inert Ingredients 1 MG Oral Tablet) / 21 (Mestranol 0.05 MG / Norethindrone 1 MG Oral Tablet) } Pack [Norinyl 1+50 28 Day] N(%) 19128065 - - 135(19.77%) - - -
Phenazopyridine hydrochloride 100 MG Oral Tablet N(%) 40236824 - - 84(12.30%) - - -

These binaries (installable software) and packages are in development.
They may not be fully stable and should be used with caution. We make no claims about them.